SCLERO.ORG
Search
Scleroderma Newsroom
ISN News Manager: Jo Frowde
Autoimmune
Media Stories
Scleroderma
ISN/Website
Autoimmune Archive
We maintain news archives for the most recent 3 years.
2019: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
2020 - 2019 - 2018 - 2017

September 2019 Autoimmune News

Characteristics and safety of tattoos in patients with systemic lupus erythematosus. Tattoos seem to be safe in SLE patients with inactive or low active disease. PubMed, Lupus, 2019 Aug 5:961203319867395. (Also see Medical Eligibility for Tattoos)

Inflammation is associated with pro-nociceptive brain connections in rheumatoid arthritis (RA) patients with concomitant fibromyalgia (FM). Here we provide the first neurobiological evidence that comorbid FM in RA may be linked to peripheral inflammation through pro-nociceptive patterns of brain connectivity. PubMed, Arthritis Rheumatol, 08/05/2019. (Also see Fibromyalgia and Symptoms and Complications of Rheumatoid Arthritis)

Proteomic and histopathological characterisation of sicca subjects and primary Sjögren's syndrome patients reveals promising tear, saliva and extracellular vesicle disease biomarkers. The tear and salivary biomarkers identified could be implemented as potential non-invasive diagnostic tools that may aid in increasing diagnostic accuracy. PubMed, Arthritis Res Ther, 2019 Jul 31;21(1):181. (Also see Diagnosis of Sjögren's Syndrome)

Safety and Efficacy of Immune Checkpoint Inhibitors (ICI) in Patients with Cancer and Preexisting Autoimmune Disease (PAD): A Nationwide Multicenter Cohort Study. The occurrence of a flare/Immune Related Adverse Effects is frequent but mostly manageable without ICI discontinuation in patients with PAD. PubMed, Arthritis Rheumatol, 08/05/2019. (Also see Cancer)

Tocilizumab and the Risk of Cardiovascular Disease (CVD): Direct Comparison Among Biologic Disease-Modifying Antirheumatic Drugs for Rheumatoid Arthritis (RA) Patients. Tocilizumab was associated with a CVD risk comparable to that for etanercept as well as a number of other biologics used for the treatment of RA. PubMed, Arthritis Care Res (Hoboken), 2019 Aug;71(8):1004-1018. (Also see Treatments for Rheumatoid Arthritis and Clinical Trials)

Prevalence and risk factors for osteoporosis in individuals with chronic obstructive pulmonary disease (COPD): a systematic review and meta-analysis. Osteoporosis is prevalent in individuals with COPD and the prevalence appears to be high and similar in many countries. PubMed, Chest, 07/25/2019. (Also see Osteoporosis)

Imbalance between CD8+CD28+ and CD8+CD28- T-cell subsets and its clinical significance in patients with systemic lupus erythematosus. These data suggest that high expression of Fas, FasL and IL-6 and low expression of CTLA-4 by the CD8+CD28+ T-cell subset promotes the activation-induced cell death of the CD8+CD28+ T-cell subset. PubMed, Lupus, 2019 Aug 9:961203319867130. (Also see Causes of Lupus and B Cells and T Cells)

Plasma α-L-fucosidase-1 in patients with Sjögren's syndrome (SS) and other rheumatic disorders. This preliminary result should encourage further research on α-L-FUCA-1 as a possible differential serological marker of SS. PubMed, Int J Rheum Dis, 08/16/2019. (Also see Diagnosis of Sjögren's Syndrome)

Serum neopterin and ischemia modified albumin (IMA) levels are associated with the disease activity of adult immunoglobulin A vasculitis (Henoch-Schönlein purpura). Roles of high-sensitivity C-reactive protein, neopterin and IMA as potential markers of diagnosis and disease activity seem to be worth studying in future studies with larger study groups. PubMed, Int J Rheum Dis, 08/14/2019. (Also see Vasculitis)

KIR3DL1/S1 Allotypes Contribute Differentially to the Development of Behçet Disease. To our knowledge, this is the first analysis of KIR3DL1/S1 allelic variation in Behçet disease and may provide insight into the pathogenic role of HLA-B*51 and its interaction with KIR3DL1/S1. PubMed, J Immunol, 08/12/2019. (Also see Behçet's Disease)

Go to Autoimmune News: August 2019
 

We have the world's best supporters! See ISN News.

 

SCLERO.ORG is the world's leading nonprofit for trustworthy research, support, education and awareness for scleroderma and related illnesses. We are a 501(c)(3) U.S.-based public charitable foundation, established in 2002. Meet Our Team. Donations may also be mailed to:

International Scleroderma Network (ISN)
7455 France Ave So #266
Edina, MN 55435-4702 USA
Email [email protected]. Disclaimer. Privacy Policy.
 

The most important thing in the world to know about scleroderma is sclero.org!